Research Topics
Species | Kenji TamuraSummaryAffiliation: Kinki University Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Gefitinib in non-small cell lung cancerKenji Tamura
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Expert Opin Pharmacother 6:985-93. 2005..Appropriate patient selection by clinical characteristics or genetical information is needed, both for future clinical trials of gefitinib and its routine use in the clinic among patients with advanced NSCLC...- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week coursesKenji Tamura
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
Cancer Chemother Pharmacol 60:285-93. 2007.... 
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthaseTakafumi Okabe
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
Mol Cancer Ther 7:599-606. 2008....- A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904)Takayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka 589 8511, Japan
Jpn J Clin Oncol 40:992-4. 2010..We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies... - Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumorsToshio Shimizu
Department of Medical Oncology, Kinki University School of Medicine, Ohno Higashi, Osaka Sayama, Japan
Cancer Chemother Pharmacol 65:243-50. 2010..We have performed a phase I study to determine the safety profile, pharmacokinetics, and antitumor activity of D-19575 in Japanese patients with advanced solid tumors.. - Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancerTomohiro Ozaki
Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
Anticancer Res 27:2657-65. 2007..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel... - Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cellsMasato Ikeda
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
Cancer Lett 248:292-8. 2007..Furthermore, depletion of survivin resulted in G(2)-M arrest, suggesting that down-regulation of survivin by p53 contributes to the p53-dependent G(2)-M checkpoint triggered by DNA damage... - Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplificationTakafumi Okabe
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Cancer Res 67:2046-53. 2007..These results reveal distinct biochemical properties of endogenous mutant forms of EGFR expressed in NSCLC cell lines and may have implications for treatment of this condition... - Amrubicin for non-small-cell lung cancer and small-cell lung cancerTakayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Invest New Drugs 25:499-504. 2007..6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer... - Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group studyIsamu Okamoto
Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
J Clin Oncol 28:5240-6. 2010.... - A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patientsHiroyasu Kaneda
Department of Medical Oncology, Kinki University School of Medicine, Osaka 589-8511, Japan
Anticancer Res 26:2479-85. 2006..CONCLUSION: These data suggest that the combination of CPT-11 and AMR is not tolerated, as it mediates an unexpectedly strong myelosuppressive effect, and is inactive against both NSCLC and SCLC... - Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancerHiroyasu Kaneda
Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
Lung Cancer 46:247-54. 2004..CONCLUSIONS: Gefitinib provided clinical benefit for the following factors 'female', 'good PS' and 'non-smoker'. A low smoking index is reported as a novel predictive prognostic factor following a single regimen of gefitinib... - Pemetrexed-induced edema of the eyelidTakayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
Lung Cancer 54:241-2. 2006..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known... - Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycinKimio Yonesaka
Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
Int J Cancer 118:812-20. 2006..siRNA targeting of survivin could be potentially useful for increasing sensitivity to anticancer drugs, especially in drug-resistant cells with mutated p53... - Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experienceToshio Shimizu
Department of Medical Oncology, Kinki University Nara Hospital, 1248 1 Otoda cho, Ikoma, Nara, 630 0293, Japan
Int J Clin Oncol 12:218-23. 2007..The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer. In Japan, oxaliplatin was approved in April 2005... - Skeletal metastases in non-small cell lung cancer: a retrospective studyAsuka Tsuya
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama City, Osaka 589 8511, Japan
Lung Cancer 57:229-32. 2007..Therefore, we planned a retrospective study to investigate the clinical impact of SREs, and to compare differences in the therapeutic outcome between patients with and without skeletal metastases or SRE... - Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?Takayasu Kurata
Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
J Thorac Oncol 1:684-91. 2006.... - Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cellsTakefumi Komiya
Division of Medical Oncology, Kinki University School of Medicine, 377 2 Ohnohigashi, 589 8511, Osakasayama City, Osaka, Japan
Cancer Chemother Pharmacol 51:202-8. 2003..The objective of this study was to determine the cytotoxicity of ritterazine B to non-small-cell lung cancer (NSCLC) cells in vitro and its effects on the cell cycle and apoptosis... - Molecular target-based cancer therapy: tyrosine kinase inhibitorsKenji Tamura
Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Int J Clin Oncol 8:207-11. 2003..Early data show that they are generally well tolerated and have provided evidence of against activity tumors. HER-TK inhibitors are likely to have a substantial impact on the treatment of cancer patients... - Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MSKazuko Matsumoto
Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
J Proteome Res 8:457-62. 2009..Our results suggest that glycosylation analysis may provide useful information for determining clinical cancer therapy and provide novel insight into biomarker studies using glycobiological tools in the field of breast cancer... - [Targeted therapies for lung cancer]Kenji Tamura
Rinsho Ketsueki 49:616-21. 2008 - Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancerGyo Asai
Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
J Thorac Oncol 1:226-30. 2006..This combination therapy must be planned only after careful consideration of the drug-drug interaction... - Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902Hiroshi Saito
Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki Aichi, Japan
J Clin Oncol 24:5247-52. 2006..We amended the protocol to evaluate IP after EP with concurrent twice-daily TRT in a single-arm phase II study because of an unacceptable toxicity in IPE... - Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinibMasahiko Ando
Department of Preventive Services, Kyoto University School of Public Health, Kyoto, Japan
J Clin Oncol 24:2549-56. 2006..We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non-small-cell lung cancer (NSCLC)... - Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancerMakiko Ono
Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo 104 0045, Japan
Jpn J Clin Oncol 38:567-70. 2008..This patient is thought to be a rare case of secondary leukemia, since the leukemia might have been caused by hormonal therapy and regional radiation without chemotherapy... - Effects of airborne particulate matter on respiratory morbidity in asthmatic childrenLu Ma
Department of Public Health, Hyogo College of Medicine, Japan
J Epidemiol 18:97-110. 2008..The effects of airborne particulate matter (PM) are a major human health concern. In this panel study, we evaluated the acute effects of exposure to PM on peak expiratory flow (PEF) and wheezing in children... - [Effects of quantity of Japanese cedar pollen, air pollution and urbanization on allergic rhinitis morbidity in Ibaraki prefecture]Wu Chunling
Endo Otolaryngologic Clinic
Nippon Koshu Eisei Zasshi 49:631-42. 2002..As local factors increasing the morbidity of allergic rhinitis in the records, air pollution, urbanization and a greater availability of medical resources were indicated...